Ligan, Gilmhar B.
HRN: 24-18-63 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/05/2023
CEFUROXIME 500MG (TAB)
12/05/2023
12/12/2023
ORAL
500mg
BID
Lefort Fracture Type III
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes